Oligonucleotides as inhibitors of human immunodeficiency virus

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 3, 1999, Pages 323-331

  Field, A Kirk ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOMIVIRSEN; OLIGONUCLEOTIDE; TRECOVIRSEN; ZINTEVIR;

ANTIVIRAL ACTIVITY; CHEMICAL MODIFICATION; DRUG DESIGN; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NUCLEOTIDE SEQUENCE; RETINITIS; REVIEW; VIRUS ADSORPTION; VIRUS INHIBITION; VIRUS TRANSCRIPTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADSORPTION; ANIMALS; ANTI-HIV AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION, VIRAL; GENE THERAPY; HIV; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1 REVERSE TRANSCRIPTASE; MACACA FASCICULARIS; MICE; MICE, SCID; NUCLEIC ACID CONFORMATION; OLIGODEOXYRIBONUCLEOTIDES; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; RATS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; THIONUCLEOTIDES; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0033056726     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Field AK: Interferon induction by polynucleotides. In: Selective Inhibitors of Viral Functions. Carter WA (Ed), CRC Press Cleveland, Ohio (1973):149-176.
2. Krown SE, Kerr D, Stewart WE, Field AK, Oettgen HF: Phase I trials of poly(I,C) complexes in advanced cancer. J Biol Response Mod (1985) 4:640-649.
3. Stephenson ML, Zamecnik PC: Inhibition of Rous sarcoma virus RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA (1978) 75:285-288. • Seminal paper on antisense ONs.
4. Zamecnik PC, Stephenson ML: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA (1978) 75:280-284. • Seminal papers on antisense ONs.
5. Kilkuskie RE, Field AK: Antisense inhibition of virus infections. In: Gene Therapy, Advances in Pharmacology, August JT (Ed), (1997) 40:437-483. • Thorough review of antisense ONs as antiviral agents.
6. Azad RF, Brown-Driver V, Buckheit RW Jr, Anderson KP: Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs. Antiviral Res (1995) 28:101-111.
7. Field AK: Viral targets for antisense oligonucleotiedes: a mini review. Antiviral Res (1998) 37:67-81.
8. Jairath S, Vargas PB, Hamlin HA, Field AK, Kilkuskie RE: Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides. Antiviral Res (1997) 33:201-213. • In situ demonstration of the mechanism of action of an antisense ON.
9. Pari GS, Field AK, Smith JA: Potent antiviral activity of an antisense oligonucleotide complementary to the intronexon boundary of human cytomegalovirus genes UL36 and UL37. Antimicrob Agents Chemother (1995) 39:1157-1161. • Fulfilling the criteria of antisense using an antiviral ON.
10. Crooke ST: Advances in understanding the pharmacological properties of antisense oligonucleotides. In: Gene Therapy, Advances in Pharmacology. August JT (Ed), (1997) 40:1-49. • Excellent review of the concepts and realities of developing antisense ON drugs.
11. Crooke ST, Graham MJ, Zuckerman JE, Brooks D, Conklin BS, Cummins LL, Greig MJ, Guinosso CJ, Kombust D, Manoharan M, Sasmor HM, Schleich T, Tivel KL, Griffey RH: Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J Pharmacol Exp Ther (1996) 277:923-937.
12. Field AK, Goodchild J: Antisense oligonucleotiedes: Rational drug design for genetic pharmacology. Exp Opin Invest Drugs (1995) 4:799-821.
13. Agrawal S, Temsamani J: Comparative pharmcokinetics of antisense oligonucleotides. In: Molecular Medicine: Antisense Therapeutics. Agrawal S (Ed), Humana Press, Totowa, New Jersey (1996):247-270.
14. Temsamani J, Agrawal S: Antisense oligonucleotides as antiviral agents. Advances Antiviral Drug Design (1996) 2:1-39.
15. Kuwasaki T, Hosono K, Takai K, Ushijima K, Nakashima H, Saito T, Yamamoto N, Takaku H: Hairpin antisense oligonucleotides containing 2′-methoxynucleosides with base-pairing in the stem region at the 3′-end: penetration, localization, and Anti-HIV activity. Biochem Biophys Res Commun (1996) 228:623-631.
16. Ojwang J, Elbaggari A, Marshall HB, Jayaraman K, McGrath MS, Rando RF: Inhibition of human immunodeficiency virus type 1 activity in vitro by oligonucleotides composed entirely of guanosine and thymidine. J Acquir Immune Defic Syndr (1994) 7:560-570.
17. Rando RF: Oligonucleotides as inhibitors of the human immunodeficiency virus type 1. Curr Res Mol Ther (1998) 1:67-75. • Thorough review of ON inhibition of HIV.
18. Fennewald SM, Rando RF: Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides. J Biol Chem (1995) 270:21718-21721.
19. Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL, Stein CA: Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem (1995) 270:2620-2627.
20. Krieg AM, Yi A-K, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 374:546-549.
21. Stein CA, Krieg AM: Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev (1994) 4:67-69. • Suggested criteria for defining antisense activity of ONs.
22. Zamecnik PC, Goodchild J, Taguchi Y, Sarin PS: Inhibition of replication and expression of human T-cell lymphtropic virus type III in cultured cells by exogenous synthetic oligoncleotides complementary to viral RNA. Proc Natl Acad Sci USA (1986) 83:4143-4146. • First use of ONs to inhibit HIV replication.
23. Goodchild J, Agrawal S, Civeira MP, Sarin PS, Sun D, Zamecnik PC: Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides. Proc Natl Acad Sci USA (1988) 85:5507-5511.
24. Agrawal S, Ikeuchi T, Sun D, Sarin PS, Konopka A, Maizel J, Zamecnik PC: Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues. Proc Natl Acad Sci USA (1989) 86:7790-7794.
25. Agrawal S, Tang JY: GEM 91 - an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS. Antisense Res Dev (1992) 2:261-266. • First description of GEM-91, later to enter clinical trials against HIV in AIDS patients.
26. Lisziewicz J, Sun D, Metelev V, Zamecnik P, Gallo RC, Agrawal S: Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates. Proc Natl Acad Sci USA (1993) 90:3860-3864.
27. Lisziewicz J, Sun D, Weichold FF, Thierry AR, Lusso P, Tang J, Gallo RC, Agrawal S: Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells. Proc Natl Acad Sci USA (1994) 91:7942-7946.
28. Yamaguchi K, Papp B, Zhang D, Ali AN, Agrawal S, Bym RA: The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (1997) 13:545-554.
29. Veal GJ, Agrawal S, Bym RA: Synergistic inhibition of HIV-1 by an antisense oligonucleotide and nucleoside analog reverse transcriptase inhibitors. Antiviral Res (1998) 38:63-73.
30. Matsukura M, Zon G, Shinozuka K, Stein CA, Mitsuya H, Cohen JS, Broder S: Synthesis of phosphorothioate analogues of oligodeoxynucleotides and their antiviral activity against human immunodeficiency virus (HIV). Gene (1988) 72:343-347.
31. Matsukura M, Zon G, Shinozuka K, Robert-Guroff M, Shimada T, Stein CA, Mitsuya H, Wong-Staal F, Cohen JS, Broder S: Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci USA (1989) 86:4244-4248.
32. Anazodo MI, Wainberg MA, Friesen AD, Wright JA: Sequence-specific inhibition of gene expression by a novel antisense oligodeoxynucleotide phosphorothioate directed against a nonregulatory region of the human immunodeficiency virus type 1 genome. J Virol (1995) 69:1794-1801. • Excellent demonstration of antisense ON HIV inhibition.
33. Bordier B, Perala-Heape M, Degols G, Lebleu B, Litvak S, Sarih-Cottin L, Helene C: Sequence-specific inhibition of human immunodeficiency virus (HIV) reverse transcription by antisense oligonucleotides: comparative study in cell-free assays and in HIV-infected cells. Proc Natl Acad Sci USA (1995) 92:9383-9387. • Excellent demonstration of antisense ON HIV inhibition.
34. Skripkin E, Paillart JC, Marquet R, Blumenfeld M, Ehresmann B, Ehresmann C: Mechanisms of inhibition of in vitro dimerization of HIV type I RNA by sense and antisense oligonucleotides. J Biol Chem (1996) 271:28612-28817.
35. Lodmell JS, Paillart JC, Mignot D, Ehresmann B, Ehresmann C, Marquet R: Oligonucleotide-mediated inhbitition of genomic RNA dimerization of HIV-1 strains MAL and LAI: a comparative analysis. Antisense Nucleic Acid Drug Dev (1998) 8:517-529.
36. Player MR, Maitra RK, Silverman RH, Torrence PF: Targeting RNase L to human immunodeficiency virus RNA with 2-5A-antisense. Antivir Chem Chemother (1998) 9:225-231.
37. Boulmé F, Perrälä-Heape M, Sarih-Cottin L, Litvak S: Specific inhibition of in vitro reverse transcription using antisense oligonucleotides targeted to the TAR regions of HIV-1 and HIV-2. Biochem Biophys Acta (1997) 1351:249-255.
38. Boulmé F, Freund F, Moreau S, Nielsen PE, Gryaznov S, Toulmé JJ, Litvak S: Modified (PNA, 2′-O-methyl and phosphoramidate) anti-TAR antisense oligonucleotides as atrong and specific inhibitors of in vitro HIV-1 reverse transcription. Nucleic Acids Res (1998) 26:5492-5500.
39. Yeung MC, Geertsma F, Liu J, Lau AS: Inhibition of HIV-1 gp120-induced apoptosis in neuroblastoma SK-N-SH cells by an antisense oligodeoxynucleotide against p53. AIDS (1998) 12:349-354.
40. Nelson JS, Giver L, Ellington AD, Letsinger RL: Incorporation of a non-nucleotide bridge into hairpin oligonucleotides capable of high-affinity binding to the Rev protein of HIV-1. Biochemistry (1996) 35:5339-5344.
41. Matsukura M, Shinozuka K, Zon G, Mitsuya H, Reitz M, Cohen JS, Broder S: Phosphorothioate analogs of oligodeoxynucleotides: Inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci USA (1987) 84:7706-7710.
42. Stein CA, Cleary AM, Yakubov L, Lederman S: Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of human immunodeficiency virus type 1 gp120. Antisense Res Dev (1993) 3:19-31. • Demonstration of the mechanism of ON inhibition of virus adsorption.
43. Wyatt JR, Vickers TA, Roberson JL, Buckeit RW Jr, Klimkait T, DeBaets E, Davis PW, Rayner B, Imbach JL, Ecker DJ: Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc Natl Acad Sci USA (1994) 91:1356-1360.
44. Buckheit Jr RW, Roberson JL, Lackman-Smith C, Wyatt JR, Vickers TA, Ecker DJ: Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320). AIDS Res Hum Retroviruses (1994) 10:1497-1506.
45. Agatsuma T, Yamamoto I, Furukawa H, Nishigaki T: Guanine-rich oligonucleotide modified at the 5′ terminal by dimethoxytrityl residue inhibits HIV-1 replication by specific interaction with the envelope glycoprotein. Antiviral Res (1996) 31:137-148.
46. Lederman S, Sullivan G, Benimetskaya L, Lowy I, Land K, Khaled Z, Cleary AM, Yakubov L, Stein CA: Polydeoxyguanine motifs in a 12-mer phosphorothioate oligodeoxynucleotide augment binding to the v3 loop of HIV-1 gp120 and potency of HIV-1 inhibition independently of G-tetrad formation. Antisense Nucleic Acid Drug Dev (1996) 6:281-289.
47. Hotoda H, Koizumi M, Koga R, Kaneko M, Momota K, Ohmine T, Furukawa H, Agatsuma T, Nishigaki T, Sone J, Tsutsumi S, Kosaka T, Abe K, Kimura S, Shimada K: Biologically active oligodeoxyribonucleotides. 5. 5′-end-substituted d(TGGGAG) possesses anti-human immunodeficiency virus type 1 activity by forming a G-quadruplex structure. J Med Chem (1998) 41:3655-3663.
48. Furukawa H, Momota K, Agatsuma T, Yamamoto I, Kimura S, Shimada K: Mechanism of inhibition of HIV-1 infection in vitro by guanine-rich oligonucleotides modified at the 5′ terminal by dimethoxytrityl residue. Nucleic Acids Res (1994) 22:5621-5627.
49. Esté JA, Proost P, Struyf S, Wuyts A, Van Damme J, De Clercq E, Schols D: Interaction of the HIV fusion inhibitor AR177 (Zintevir) with the HIV type 1 second receptor. Antiviral Res (1997) 34 (2):A41.
50. Esté JA, Schols D, Witvrouw M, Cherepanov P, Pannecouque C, Rando RF, Debyser Z, Desmyter J, De Clercq E: Human immunodeficiency virus gp120 as the primary target of action of AR177 (Zintevir). Antiviral Res (1997) 34(2):A57.
51. Esté JA, Cabrera C, Schols D, Cherepanov P, Gutierrez A, Witvrouw M, Pannecouque C, Debyser Z, Rando RF, Clotet B, Desmyter J, De Clercq E: Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Mol Pharmacol (1998) 53:340-345.
52. Hatta T, Kim S-G, Nakashima H, Yamamoto N, Sakamoto K, Yokoyama S, Takaku H: Mechanisms of the inhibition of reverse transcription by unmodified and modified antisense oligonucleotides. FEBS Lett (1993) 330:161-164.
53. Boiziau C, Thuong NT, Toulmé J-J: Mechanisms of the inhibition of reverse transcription by antisense oligonucleotides. Proc Natl Acad Sci USA (1992) 89:768-772.
54. Marshall WS, Beaton G, Stein CA, Matsukura M, Caruthers MH: Inhibition of human immunodeficiency virus activity by phosphorothioate oligodeoxycytidine. Proc Natl Acad Sci USA (1992) 89:6265-6269.
55. Marshall WS, Caruthers MH: Phosphorodithioate DNA as a potential therapeutic drug. Science (1993) 259:1564-1570.
56. Austermann S, Kruhoffer M, Grosse F: Inhibition of human immunodeficiency virus type 1 reverse transcriptase by 3′-blocked oligonucleotide primers. Biochem Pharmacol (1992) 43:2581-2589.
57. Idriss H, Stammers DK: Inhibition of HIV-1 reverse transcriptase by defined template/primer DNA oligonucleotides: effect of template length and binding characteristics. J Enzyme Inhib (1994) 8:97-112.
58. Boiziau C, Tarrago-Litvak L, Sinha ND, Moreau S, Litvak S, Toulmé J-J: Antisense oligonucleotides inhibit in vitro cDNA synthesis by HIV-1 reverse transcriptase. Antisense Nucleic Acid Drug Dev (1996) 6:103-109.
59. Hatta T, Takai K, Yokoyama S, Nakashima H, Yamamoto N, Takaku H: Phosphorothioate oligonucleotides block reverse transcription by the Rnase H activity associated with the HIV-1 polymerase. Biochem Biophys Res Commun (1995) 211:1041-1046.
60. El Dirani-Diab R, Sarih-Cottin L, Delard B, Dumon B, Moreau S, Toulmé J-J, Fleury H, Litvak S: Phosphorothioate oligonucleotides derived from human immunodeficiency virus type 1 (HIV-1) primer tRNALys3 are strong inhibitors of HIV-1 reverse transcriptase and arrest viral replication in infected cells. Antimicrob Agents Chemother (1997) 41:2141-2148.
61. Volkmann S, Jendis J, Frauendorf A, Moelling K: Inhibition of HIV-1 reverse transcription by triple-helix forming oligonucleotides with viral RNA. Nucleic Acids Res (1995) 23:1204-1212.
62. Tsukahara S, Suzuki J, Hiratou T, Takai K, Koyanagi Y, Yamamoto N, Takaku H: Inhibition of HIV-1 replication by triple-helix-forming phosphorothioate oligonucleotides targeted to the polypurine tract. Biochem Biophys Res Commun (1997) 233:742-747.
63. Hiratou T, Tsukahara S, Takai K, Koyanagi Y, Yamamoto N, Takaku H: Inhibition of HIV-1 replication by foldback triple-helix forming oligonucleotides. Nucleic Acids Symp Ser (1997) 37:221-222.
64. Ojwang JO, Buckheit RW, Pommier Y, Mazumder A, De Vreese K, Esté JA, Reymen D, Pallansch LA, Lackman-Smith C, Wallace TL, De Clercq E, McGrath MS, Rando RF: T30177, an oligonucleotide stablilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob Agents Chemother (1995) 39:2426-2435. • Landmark paper in describing anti-HIV activity of T-30177 (Zintevir, AR-177).
65. Rando RF, Ojwang JO, Elbaggari A, Reyes GR, Tinder R, McGrath MS, Hogan ME: Suppression of human immunodeficiency virus type 1 activity in vitro by oligonucleotides which form intramolecular tetrads. J Biol Chem (1995) 270:1754-1760. • G quartet formation and the inhibition of HIV.
66. Jing N, Rando RF, Pommier Y, Hogan ME: Ion selective folding of loop domains in a potent anti-HIV oligonucleotide. Biochemistry (1997) 36:12498-12505.
67. Mazumder A, Neamati N, Ojwang JO, Sunder S, Rando RF, Pommier Y: Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures. Biochemistry (1996) 35:13762-13771.
68. Rando RF, Hogan ME: Biological activity of guanosine quartet-forming oligonucleotides. In: Applied Antisense Oligonucleotide Technology. Stein CA, Krieg AM (Eds), Wiley-Liss Inc (1998):335-352.
69. Jing N, Gao X, Rando RF, Hogan ME: Potassium-induced loop conformational transition of a potent anti-HIV oligonucleotide. J Biomol Struct Dyn (1997) 15:573-585.
70. Jing N, Hogan ME: Structure-activity of tetrad-forming oligonucleotides as a potent anti-HIV therapeutic drug. J Biol Chem (1998) 273:34922-34999. • Detailed review of the G quartet formation and the biological activity.
71. Tramontano E, Colla PL, Cheng YC: Biochemical characterization of the HIV-1 integrase 3′-processing activity and its inhibition by phosphorothioate oligonucleotides. Biochemistry (1998) 37:7237-7243.
72. Svinarchuk F, Monnot M, Merle A, Malvy C, Fermandjian S: The high stability of the triple helices formed between short purine oligonucleotides and SIV/HIV-2 vpx genes is determined by the targeted DNA structure. Nucleic Acids Res (1995) 23:3831-3836.
73. Jendis J, Strack B, Moelling K: Inhibition of replication of drug-resistant HIV type 1 isolates by polypurine tract-specific oligodeoxynucleotide TFO A. AIDS Res Hum Retroviruses (1998) 14:999-1005.
74. Giovannangeli C, Diviacco S, Labrousse V, Gryaznov S, Chameau P, Helene C: Accessibility of nuclear DNA to triplex-forming oligonucleotides: the integrated HIV-1 provirus as a target. Proc Natl Acad Sci USA (1997) 94:79-84.
75. Bennett CF, Dean N, Ecker DJ, Monia BP: Pharmacology of antisense therapeutic agents. In: Molecular Medicine: Antisense Therapeutics. Agrawal S (Ed), Humana Press, Totowa, New Jersey (1996):13-16.
76. Szymkowski DE: Developing antisense oligonucleotides from the laboratory to clinical trials. Drug Discov Today (1996) 1:415-428. • Interesting review of the practical challenges for practical development of antisense ONs.
77. Mosier DE, Guilizia RJ, Baird SM, Wilson DB: Transfer of a functional immune system to mice with severe combined immunodeficiency. Nature (1988) 335:256-259.
78. Namikawa R, Kaneshima H, Lieberman M, Weissman IL, McCune JM: Infection of the SCID-hu mouse by HIV-1. Science (1988) 242:1684-1686.
79. Agatsuma T, Abe K, Furukawa H, Koga R, Koizumi M, Hotoda H, Kaneko M: Protection of hu-PBL/beige mice from HIV-1 infection by a 6-mer modified oligonucleotide, R-95288. Antiviral Res (1997) 34:121-130.
80. Furukawa H, Momota K, Agatsuma T, Yamamoto I, Kimura S, Shimada K: Identification of a phosphodiester hexanucleotide that inhibitis HIV-1 infection in vitro on covalent linkage of its 5′-end with a dimethoxytrityl residue. Antisense Nucleic Acid Drug Dev (1997) 7:167-175.
81. Stoddart CA, Rabin L, Hincenbergs M, Moreno M, Linquist-Stepps V, Leeds JM, Truong LA, Wyatt JR, Ecker DJ, McCune JM: Inhibition of human immunodeficiency virus type 1 infection in SCID-hu Thy/Liv mice by the G-quartet-forming oligonucleotide, ISIS 5320. Antimicrob Agents Chemother (1998) 42:2113-2115.
82. Zhang R, Diasio RB, Lu Z, Liu T, Jiang Z, Galbraith WM, Agrawal S: Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol (1995) 49:929-939.
83. Cornish KG, Iversen P, Smith P, Ameson M, Bayever E: Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey. Pharmacol Commun (1993) 3:239-247.
84. Galbraith WM, Hobson WC, Giclas PC, Schechter PJ, Agrawal S: Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev (1994) 4:201-206.
85. Grindel JM, Musick TJ, Jiang Z, Roskey A, Agrawal S: Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion. Antisense Nucleic Acid Drug Dev (1998) 8:43-52.
86. Zhang R, Yan J, Shahinian H, Amin G, Lu Z, Liu T, Saag MS, Jiang Z, Temsamani J, Martin RR, Schechter PJ, Agrawal S, Diasio RB: Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin Pharmacol Ther (1995) 58:44-53. • Description of phase I clinical studies of a PS ON administered as an iv infusion.
87. Wallace TL, Bazemore SA, Kombrust DJ, Cossum PA: Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys. J Pharmacol Exp Ther (1996) 278:1306-1312.
88. Wallace TL, Bazemore SA, Kombrust DJ, Cossum PA: Repeat-dose toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after bolus intravenous administration to cynomolgus monkeys. J Pharmacol Exp Ther (1996) 278:1313-1317.
89. Wallace TL, Bazemore SA, Holm K, Markham PM, Shea JP, Chaudhary N, Cossum PA: Pharmacokinetics and distribution of a 33P-labeled anti-human immunodeficiency virus oligonucleotide (AR177) after single-and multiple-dose intravenous administration to rats. J Pharmacol Exp Ther (1997) 280:1480-1488.
90. Selvam MP, Buck SM, Blay RA, Mayner RE, Mied PA, Epstein JS: Inhibition of HIV replication by immunoliposomal antisense oligonucleotide. Antiviral Res (1996) 33:11-20.
91. Zelphati O, Imbach JL, Signoret N, Zon G, Rayner B, Leserman L: Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms. Nucleic Acids Res (1994) 22:4307-4314.
92. Field AK: Will oligonucleotides make effective drugs? Curr Res Mol Ther (1998) 1:65-66.
93. Zhang Z, Tang J-Y: Synthesis and scale-up of modified oligonucleotides. Curr Res Mol Ther (1998) 1:76-84. • Excellent review of the issues and appoaches to ON synthesis and practical large-scale production.